Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tjeerd Germans

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
International Journal of Cardiology|June 4, 2025
Genotype-negative hypertrophic cardiomyopathy: Exploring the role of cardiovascular risk factors in disease expressionStephan A C Schoonvelde, Edgar E Nollet, Peter-Paul Zwetsloot, et al.
International Journal of Cardiology|June 17, 2022
Heart failure subphenotypes based on repeated biomarker measurements are associated with clinical characteristics and adverse events (Bio-SHiFT study)Iris de Lange, Teun B Petersen, Marie de Bakker, et al.
International Journal of Cardiology|March 10, 2017
Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT studyNick van Boven, K Martijn Akkerhuis, Sharda S Anroedh, et al.
Cardiovascular Research|July 2, 2025
Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trialBeau Olivier van Driel, Stephan A C Schoonvelde, Sonia Borodzicz-Jazdzyk, et al.
Open Heart|May 28, 2025
Assessing the psychometric properties of generic (EQ-5D-5L) and disease-specific (KCCQ) quality of life in patients with hypertrophic cardiomyopathy in the AFFECT-HCM studyIsabell Wiethoff, Stephan A C Schoonvelde, Rudolf A de Boer, et al.
Biology of Sex Differences|May 17, 2023
Sex-based differences in cardiovascular proteomic profiles and their associations with adverse outcomes in patients with chronic heart failureMarie de Bakker, Teun B Petersen, K Martijn Akkerhuis, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|November 9, 2024
Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM studyStephan A C Schoonvelde, Isabell Wiethoff, Peter-Paul Zwetsloot, et al.
Cells|November 27, 2021
Distinct Metabolomic Signatures in Preclinical and Obstructive Hypertrophic CardiomyopathyMaike Schuldt, Beau van Driel, Sila Algül, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 25, 2007
Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathyPaul Knaapen, Tjeerd Germans, Paolo G Camici, et al.
European Heart Journal. Digital Health|December 4, 2023
Machine learning-based biomarker profile derived from 4210 serially measured proteins predicts clinical outcome of patients with heart failureMarie de Bakker, Teun B Petersen, Anja J Rueten-Budde, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
International Journal of Cardiology|June 4, 2025
Genotype-negative hypertrophic cardiomyopathy: Exploring the role of cardiovascular risk factors in disease expressionStephan A C Schoonvelde, Edgar E Nollet, Peter-Paul Zwetsloot, et al.
International Journal of Cardiology|June 17, 2022
Heart failure subphenotypes based on repeated biomarker measurements are associated with clinical characteristics and adverse events (Bio-SHiFT study)Iris de Lange, Teun B Petersen, Marie de Bakker, et al.
International Journal of Cardiology|March 10, 2017
Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT studyNick van Boven, K Martijn Akkerhuis, Sharda S Anroedh, et al.
Cardiovascular Research|July 2, 2025
Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trialBeau Olivier van Driel, Stephan A C Schoonvelde, Sonia Borodzicz-Jazdzyk, et al.
Open Heart|May 28, 2025
Assessing the psychometric properties of generic (EQ-5D-5L) and disease-specific (KCCQ) quality of life in patients with hypertrophic cardiomyopathy in the AFFECT-HCM studyIsabell Wiethoff, Stephan A C Schoonvelde, Rudolf A de Boer, et al.
Biology of Sex Differences|May 17, 2023
Sex-based differences in cardiovascular proteomic profiles and their associations with adverse outcomes in patients with chronic heart failureMarie de Bakker, Teun B Petersen, K Martijn Akkerhuis, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|November 9, 2024
Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM studyStephan A C Schoonvelde, Isabell Wiethoff, Peter-Paul Zwetsloot, et al.
Cells|November 27, 2021
Distinct Metabolomic Signatures in Preclinical and Obstructive Hypertrophic CardiomyopathyMaike Schuldt, Beau van Driel, Sila Algül, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 25, 2007
Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathyPaul Knaapen, Tjeerd Germans, Paolo G Camici, et al.
European Heart Journal. Digital Health|December 4, 2023
Machine learning-based biomarker profile derived from 4210 serially measured proteins predicts clinical outcome of patients with heart failureMarie de Bakker, Teun B Petersen, Anja J Rueten-Budde, et al.
Pageof 8